BioHarvest Opens the Door for Pharma Researchers to Unlock the Power of Cannabinoids
November 23rd, 2022
The medical cannabis industry will reach more than $54 billion in size by 2029, according to Data Bridge Market Research, representing a 22.1% compound annual growth rate. In addition to patients turning to state medical cannabis programs, researchers continue to uncover evidence that cannabinoids could help treat a wide range of medical conditions.
BioHarvest Sciences (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV), a pioneer in developing plant bioreactors that scale the production of active ingredients, recently announced a binding letter of intent with Royal Emerald Pharmaceuticals (REP) to supply cannabinoids to pharmaceutical companies, research institutions, and other DEA-regulated entities in the United States.
Royal Emerald Pharmaceuticals is one of only seven bulk manufacturers that the DEA allows to grow cannabis in the U.S. for FDA-approved drug-related studies.
Why It Matters: Cannabis is Reshaping Pharma
Cannabis legalization presents an existential threat to pharmaceutical companies. For instance, researchers found that more than half of nearly 3,000 self-reported cannabis users used non-prescribed cannabis to replace a prescription drug. These included pain medications, antidepressants, and arthritis medication, among others.
However, many of these individuals turn to cannabis due to the lack of efficacy in conventional pharmaceutical treatments. Research suggests that the availability of cannabis-based pharmaceuticals could become a boom to these companies, helping them provide viable alternatives to individuals that would otherwise turn to illegal substances.
REP and BHSC can offer these pharmaceutical firms consistent medical-grade cannabis products along with signature compositions patented for addressing specific indications. By growing plant cells in bioreactors, BHSC has precise control over the composition of different cannabinoids and can produce biomass at a highly attractive margin.
A Unique Technology Unlocks Value
BioHarvest’s unique technology, in which vital plant cells are grown in bioreactors, has the potential to produce different major and minor cannabinoids at increased levels of control and consistency. This could help researchers develop cures for challenges such as ADHD, pain management, sleep disorders, and anxiety that were unattainable before.
In fact, the company announced breakthrough results from its bioreactors in early November, when it produced hemp trichomes with 100x to 200x the density of plants. The CBDV and THCV contents alone in these trichomes could be game-changing, as they sell for $35,000 to $50,000 per kilogram in the open market (due to their low concentrations in hemp plants).
But for researchers, these results suggest that BHSC could scale up production of hundreds of rare cannabinoids. Each of these has the potential to treat various medical conditions, opening the door to researchers and drug makers. In addition, the company can fine-tune the mix of cannabinoids, enabling researchers to analyze the “entourage effect” in various combos.
BioHarvest Sciences (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) has found a way to produce rare cannabinoids in large quantities. These cannabinoids have the potential to be used to treat various medical conditions. With an agreement in place with REP, the company is well-positioned to help pharmaceutical companies and researchers unlock their potential.
For more information, visit the company’s website or complete the form below to download their investor presentation.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.